Compare AbbVie Inc (ABBV) vs American Electric Power Company Inc (AEP) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

American Electric Power (AEP) trades at $125.73, up 0.38% on the day, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though the company raised full-year 2026 operating EPS guidance to $6.25–$6.55, reflecting confidence in AI-driven power demand growth. Fundamentals show robust revenue growth to $21.88B in 2025 and a net income margin of 13.78%, supported by a $78 billion capital plan.

The outlook remains positive due to contracted load growth and infrastructure investments, but risks include execution of large capital expenditures and interest rate sensitivity. With a consensus price target of $140.89 and no sell ratings, Wall Street sentiment is bullish, though technical indicators suggest near-term caution amid bearish moving averages.